{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:38:15Z","timestamp":1787564295703,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fibroblast activation protein (FAP)\u2013targeted tracers have emerged as promising agents for breast cancer imaging, with recent studies demonstrating PET performance comparable to or surpassing, that of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG. Nevertheless, data comparing [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG uptake in hormone receptor and\/or HER2\u2013positive breast cancer (luminal-like vs HER2-positive) remain scarce. Aim of this study was to investigate the diagnostic performance of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 versus [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT in patients with hormone-receptor and\/or HER2-positive breast cancer, and to evaluate the uptake of both tracers stratified by molecular subtypes (luminal-like vs HER2-positive). A sub-analysis of a prospective observational trial (NCT04571086) was conducted. Patients with histologically confirmed, hormone receptor- and\/or HER2-positive breast cancer who underwent whole-body [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT in the same week for initial staging or follow-up were included. [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 or [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET-positive lesions were defined as visually increased lesion uptake compared to adjacent organ background. Semi-automatic segmentation was performed to determine SUVmax, SUVpeak, TLRpeak, total number of lesions, total tumour volume, and total tumour SUV mean. Data were compared between molecular subtypes (luminal-like vs HER2-positive).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirteen patients were included. Overall, the detection performance was comparable between [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET. The semi-quantitative analysis showed comparable mean uptake values in breast cancer lesions on [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT (SUV\n                      <jats:sub>max<\/jats:sub>\n                      : 13.4 vs. 12.9; TLR\n                      <jats:sub>peak<\/jats:sub>\n                      : 5.6 vs. 4.5) and revealed no significant differences in the median lesion count (4.5 vs. 5), mean total tumour volume (71.5 vs. 73.2 mL), or mean total tumour SUV\n                      <jats:sub>mean<\/jats:sub>\n                      (5.4 vs. 5.4). No substantial differences between molecular subtypes (luminal-like vs. HER2-positive) were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In this small exploratory cohort, comparable uptake patterns in [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46- and [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-positive breast cancer lesions were observed across subtypes, underscoring the potential of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 as a versatile imaging tool. Future studies in larger cohorts are warranted to explore the potential of FAP-targeted theranostics in different breast cancer subtypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      68-Ga-FAPI-PET for Tumor Detection: A Prospective Observational Trial, NCT04571086, 09-15-2020,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04571086\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT04571086<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01390-3","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:24:19Z","timestamp":1773390259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison between [68Ga]Ga-FAPI-46 and [18F]FDG PET\/CT uptake in luminal-like vs. HER2-positive breast cancer"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4380-1629","authenticated-orcid":false,"given":"Alina Toni","family":"K\u00fcper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia Carrilho","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Magaly","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieva","family":"Ciuciulkaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilektra Antonia","family":"Mavroeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Welt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Hammersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Fragoso","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Djaileb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang Peter","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherko","family":"K\u00fcmmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"3","key":"1390_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1390_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03502-3.","journal-title":"Nat Med"},{"issue":"3","key":"1390_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","volume":"5","author":"O Yersal","year":"2014","unstructured":"Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412\u201324.","journal-title":"World J Clin Oncol"},{"key":"1390_CR4","doi-asserted-by":"crossref","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE, G\u00f3mez-Valles FO, Ram\u00edrez-Valdespino CA. Subtypes of Breast Cancer. In: Mayrovitz HN, editor. Breast Cancer. Brisbane (AU): Exon Publications Copyright: The Authors.; The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced.; 2022.","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"issue":"4","key":"1390_CR5","first-page":"290","volume":"67","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer-Major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290\u2013303.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1390_CR6","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM-SNMMI guideline on the role of 2-[(18)F]FDG PET\/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024;51(9):2706\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"20","key":"1390_CR7","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1200\/JCO.2000.18.20.3495","volume":"18","author":"N Avril","year":"2000","unstructured":"Avril N, Ros\u00e9 CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18(20):3495\u2013502.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1390_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux D, Giacchetti S, Moretti JL, Porcher R, Espi\u00e9 M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1390_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/jnumed.123.266938","volume":"65","author":"D Mankoff","year":"2024","unstructured":"Mankoff D, Balogov\u00e1 S, Dunnwald L, Dehdashti F, DeVries E, Evangelista L, et al. Summary: SNMMI procedure Standard\/EANM practice guideline for Estrogen receptor imaging of patients with breast cancer using 16\u03b1-[(18)F]Fluoro-17\u03b2-Estradiol PET. J Nucl Med. 2024;65(2):221\u20133.","journal-title":"J Nucl Med"},{"issue":"10","key":"1390_CR10","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.2967\/jnumed.124.267636","volume":"65","author":"B Eisses","year":"2024","unstructured":"Eisses B, van Geel JJL, Brouwers AH, Bensch F, Elias SG, Kuip EJM, et al. Whole-body HER2 heterogeneity identified on HER2 PET in HER2-negative, -low, and -positive metastatic breast cancer. J Nucl Med. 2024;65(10):1540\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"1390_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00610-6","volume":"10","author":"M Mileva","year":"2024","unstructured":"Mileva M, de Vries EGE, Guiot T, Wimana Z, Deleu AL, Schr\u00f6der CP, et al. Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial). NPJ Breast Cancer. 2024;10(1):4.","journal-title":"NPJ Breast Cancer"},{"key":"1390_CR12","doi-asserted-by":"publisher","unstructured":"Parihar AS, Vaz S, Sutcliffe S, Pant N, Schoones JW, Ulaner GA. (18)F-Fluoroestradiol PET\/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive breast cancer: A Systematic Review and Meta nalysis. J Nucl Med. 2025;66(5):692-9.https:\/\/doi.org\/10.2967\/jnumed.124.269163.","DOI":"10.2967\/jnumed.124.269163"},{"issue":"1","key":"1390_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s44303-024-00053-z","volume":"2","author":"Y Mori","year":"2024","unstructured":"Mori Y, Novruzov E, Schmitt D, Cardinale J, Watabe T, Choyke PL, et al. Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET). NPJ Imaging. 2024;2(1):48.","journal-title":"NPJ Imaging"},{"issue":"8","key":"1390_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s12149-023-01852-x","volume":"37","author":"L Evangelista","year":"2023","unstructured":"Evangelista L, Filippi L, Schillaci O. What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature. Ann Nucl Med. 2023;37(8):442\u201350.","journal-title":"Ann Nucl Med"},{"key":"1390_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030523","author":"L Gilardi","year":"2022","unstructured":"Gilardi L, Air\u00f2 Farulla LS, Demirci E, Clerici I, Omodeo Sal\u00e8 E, Ceci F. Imaging cancer-associated fibroblasts (CAFs) with FAPi PET. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10030523.","journal-title":"Biomedicines"},{"key":"1390_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030908","author":"S Taralli","year":"2023","unstructured":"Taralli S, Lorusso M, Perrone E, Perotti G, Zagaria L, Calcagni ML. PET\/CT with fibroblast activation protein inhibitors in breast cancer: diagnostic and theranostic application-a literature review. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15030908.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1390_CR17","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s12149-021-01616-5","volume":"35","author":"H K\u00f6mek","year":"2021","unstructured":"K\u00f6mek H, Can C, G\u00fczel Y, Oru\u00e7 Z, G\u00fcndo\u011fan C, Yildirim \u00d6A. 68Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET\/CT. Ann Nucl Med. 2021;35(6):744\u201352.","journal-title":"Ann Nucl Med"},{"issue":"12","key":"1390_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s12149-021-01672-x","volume":"35","author":"U Elboga","year":"2021","unstructured":"Elboga U, Sahin E, Kus T, Cayirli YB, Aktas G, Uzun E, et al. Superiority of (68)Ga-FAPI PET\/CT scan in detecting additional lesions compared to (18)FDG PET\/CT scan in breast cancer. Ann Nucl Med. 2021;35(12):1321\u201331.","journal-title":"Ann Nucl Med"},{"issue":"12","key":"1390_CR19","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1007\/s00259-021-05378-0","volume":"48","author":"K Dendl","year":"2021","unstructured":"Dendl K, Koerber SA, Finck R, Mokoala KMG, Staudinger F, Schillings L. 68Ga-FAPI-PET\/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. 2021;48(12):4089\u2013100.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1390_CR20","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00259-020-05132-y","volume":"48","author":"S Ballal","year":"2021","unstructured":"Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, et al. Biodistribution, pharmacokinetics, dosimetry of [(68)Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [(18)F]F-FDG PET\/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 2021;48(6):1915\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1390_CR21","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1097\/RLU.0000000000004523","volume":"48","author":"S Zheng","year":"2023","unstructured":"Zheng S, Lin J, Zhu Y, Chen Y, Zhang J, Chen X, et al. 68Ga-FAPI versus 18F-FDG PET\/CT in evaluating newly diagnosed breast cancer patients: A Head-to-Head comparative study. Clin Nucl Med. 2023;48(3):e104\u20139.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1390_CR22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00259-023-06482-z","volume":"51","author":"MP Yadav","year":"2024","unstructured":"Yadav MP, Ballal S, Martin M, Roesch F, Satapathy S, Moon ES, et al. Therapeutic potential of [(177)Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment. Eur J Nucl Med Mol Imaging. 2024;51(3):805\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1390_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, Biodistribution, and preliminary dosimetry in Peptide-Targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: First-in-Humans results. J Nucl Med. 2022;63(3):415\u201323.","journal-title":"J Nucl Med"},{"issue":"11","key":"1390_CR24","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","volume":"46","author":"M Assadi","year":"2021","unstructured":"Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, et al. Feasibility and therapeutic potential of 177Lu-Fibroblast activation protein Inhibitor-46 for patients with relapsed or refractory cancers: A preliminary study. Clin Nucl Med. 2021;46(11):e523\u201330.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"1390_CR25","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50(7):1906\u201318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1390_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2967\/jnumed.123.266798","volume":"65","author":"E Sahin","year":"2024","unstructured":"Sahin E, Kus T, Aytekin A, Uzun E, Elboga U, Yilmaz L, et al. (68)Ga-FAPI PET\/CT as an alternative to (18)F-FDG PET\/CT in the imaging of invasive lobular breast carcinoma. J Nucl Med. 2024;65(4):512\u20139.","journal-title":"J Nucl Med"},{"issue":"3","key":"1390_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/RLU.0000000000004540","volume":"48","author":"Y Eshet","year":"2023","unstructured":"Eshet Y, Tau N, Apter S, Nissan N, Levanon K, Bernstein-Molho R, et al. The role of 68 Ga-FAPI PET\/CT in detection of metastatic lobular breast cancer. Clin Nucl Med. 2023;48(3):228\u201332.","journal-title":"Clin Nucl Med"},{"key":"1390_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111567","author":"K Abe","year":"2024","unstructured":"Abe K, Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Naka S, et al. Evaluation of targeted alpha therapy using [(211)At]FAPI1 in triple-negative breast cancer xenograft models. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms252111567.","journal-title":"Int J Mol Sci"},{"key":"1390_CR29","unstructured":"Liu T, Liu J, Liu J, Xu S, Yu J. [18F]AlF-NOTA-FAPI-04 PET\/CT Uptake of the Primary Tumor on PET\/CT Imaging Might Distinguish Triple Negative Breast Cancer."},{"issue":"1","key":"1390_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00765-y","volume":"11","author":"M Weber","year":"2021","unstructured":"Weber M, Jentzen W, Hofferber R, Herrmann K, Fendler WP, Conti M, et al. Evaluation of [(68)Ga]Ga-PSMA PET\/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision. EJNMMI Res. 2021;11(1):21.","journal-title":"EJNMMI Res"},{"issue":"2","key":"1390_CR31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576\u201384.","journal-title":"Radiology"},{"issue":"2","key":"1390_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1390_CR33","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-015-3070-1","volume":"42","author":"K Kitajima","year":"2015","unstructured":"Kitajima K, Fukushima K, Miyoshi Y, Nishimukai A, Hirota S, Igarashi Y, et al. Association between \u00b9\u2078F-FDG uptake and molecular subtype of breast cancer. Eur J Nucl Med Mol Imaging. 2015;42(9):1371\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1390_CR34","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00259-017-3770-9","volume":"44","author":"L Antunovic","year":"2017","unstructured":"Antunovic L, Gallivanone F, Sollini M, Sagona A, Invento A, Manfrinato G, et al. [(18)F]FDG PET\/CT features for the molecular characterization of primary breast tumors. Eur J Nucl Med Mol Imaging. 2017;44(12):1945\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1390_CR35","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s00259-025-07108-2","volume":"52","author":"W Guo","year":"2025","unstructured":"Guo W, Xu W, Meng T, Fan C, Fu H, Pang Y, et al. FAP-targeted PET\/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management. Eur J Nucl Med Mol Imaging. 2025;52(7):2317\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1390_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.152915","volume":"216","author":"S Salimifard","year":"2020","unstructured":"Salimifard S, Masjedi A, Hojjat-Farsangi M, Ghalamfarsa G, Irandoust M, Azizi G, et al. Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. Pathol Res Pract. 2020;216(5):152915.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"1390_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-00953-y","volume":"13","author":"CM de Mooij","year":"2023","unstructured":"de Mooij CM, Ploumen RAW, Nelemans PJ, Mottaghy FM, Smidt ML, van Nijnatten TJA. The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis. EJNMMI Res. 2023;13(1):5.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1390_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00259-024-06873-w","volume":"52","author":"T Liu","year":"2024","unstructured":"Liu T, Xu S, Cheng K, Pei J, Wang S, Li C, et al. Exploring the value of FAP-targeted PET\/CT in differentiating breast cancer molecular subtypes: a preliminary study. Eur J Nucl Med Mol Imaging. 2024;52(1):280\u201390.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1390_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1148\/radiol.2021204677","volume":"302","author":"P Backhaus","year":"2021","unstructured":"Backhaus P, Burg MC, Roll W, B\u00fcther F, Breyholz H-J, Weigel S, et al. Simultaneous FAPI PET\/MRI targeting the Fibroblast-Activation protein for breast cancer. Radiology. 2021;302(1):39\u201347.","journal-title":"Radiology"},{"key":"1390_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104377","volume":"198","author":"L Santos","year":"2024","unstructured":"Santos L, Moreira JN, Abrunhosa A, Gomes C. Brain metastasis: an insight into novel molecular targets for theranostic approaches. Crit Rev Oncol Hematol. 2024;198:104377.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1390_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1436009","volume":"14","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ding H, Cao J, Liu G, Chen Y, Huang Z. [(68)Ga]Ga-FAPI PET\/CT in brain tumors: comparison with [(18)F]F-FDG PET\/CT. Front Oncol. 2024;14:1436009.","journal-title":"Front Oncol"},{"issue":"1","key":"1390_CR42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3348\/kjr.2023.0840","volume":"25","author":"C Fu","year":"2024","unstructured":"Fu C, Zhang B, Guo T, Li J. Imaging evaluation of peritoneal metastasis: current and promising techniques. Korean J Radiol. 2024;25(1):86\u2013102.","journal-title":"Korean J Radiol"},{"issue":"1","key":"1390_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-025-00887-9","volume":"25","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Xu M, Wang Y, Yu F, Chen X, Wang G, et al. Characteristics of (18)F-FAPI-04 PET\/CT in patients with peritoneal metastasis and to predict treatment efficacy, a head-to-head comparison with (18)F-FDG PET\/CT. Cancer Imaging. 2025;25(1):66.","journal-title":"Cancer Imaging"},{"issue":"3","key":"1390_CR44","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cpet.2023.02.007","volume":"18","author":"Y Mori","year":"2023","unstructured":"Mori Y, Kratochwil C, Haberkorn U, Giesel FL. Fibroblast activation protein inhibitor theranostics: early clinical translation. PET Clin. 2023;18(3):419\u201328.","journal-title":"PET Clin"},{"issue":"11","key":"1390_CR45","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49(11):3651\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1390_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ph14121212","author":"S Ballal","year":"2021","unstructured":"Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, et al. First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2). Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14121212.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1390_CR47","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749","volume":"306","author":"Y Mori","year":"2023","unstructured":"Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306(2):e220749.","journal-title":"Radiology"},{"issue":"2","key":"1390_CR48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.120.245084","volume":"62","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Adeberg S, Syed M, Lindner T, Jim\u00e9nez-Franco LD, Mavriopoulou E, et al. FAPI-74 PET\/CT using either (18)F-AlF or Cold-Kit (68)Ga labeling: Biodistribution, radiation Dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62(2):201\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"1390_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s41181-021-00144-x","volume":"6","author":"T Lindner","year":"2021","unstructured":"Lindner T, Altmann A, Giesel F, Kratochwil C, Kleist C, Kr\u00e4mer S, et al. (18)F-labeled tracers targeting fibroblast activation protein. EJNMMI Radiopharm Chem. 2021;6(1):26.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"10","key":"1390_CR50","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2967\/jnumed.119.239731","volume":"61","author":"T Lindner","year":"2020","unstructured":"Lindner T, Altmann A, Kr\u00e4mer S, Kleist C, Loktev A, Kratochwil C, et al. Design and development of (99m)Tc-labeled FAPI tracers for SPECT imaging and (188)Re therapy. J Nucl Med. 2020;61(10):1507\u201313.","journal-title":"J Nucl Med"},{"key":"1390_CR51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2101852118","author":"J Millul","year":"2021","unstructured":"Millul J, Bassi G, Mock J, Elsayed A, Pellegrino C, Zana A, et al. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2101852118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1390_CR52","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1007\/s00259-021-05653-0","volume":"49","author":"P Backhaus","year":"2022","unstructured":"Backhaus P, Gierse F, Burg MC, B\u00fcther F, Asmus I, Dorten P, et al. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [(68)Ga]Ga-OncoFAP-DOTAGA. Eur J Nucl Med Mol Imaging. 2022;49(6):1822\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1390_CR53","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00259-023-06272-7","volume":"50","author":"J Millul","year":"2023","unstructured":"Millul J, Koepke L, Haridas GR, Sparrer KMJ, Mansi R, Fani M. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides. Eur J Nucl Med Mol Imaging. 2023;50(10):3050\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1390_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-020-00102-z","volume":"5","author":"ES Moon","year":"2020","unstructured":"Moon ES, Elvas F, Vliegen G, De Lombaerde S, Vangestel C, De Bruycker S, et al. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators. EJNMMI Radiopharm Chem. 2020;5(1):19.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"3","key":"1390_CR55","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2967\/jnumed.120.247882","volume":"62","author":"GA Ulaner","year":"2021","unstructured":"Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou V, Riedl CC, Lewis JS, et al. Head-to-Head evaluation of (18)F-FES and (18)F-FDG PET\/CT in metastatic invasive lobular breast cancer. J Nucl Med. 2021;62(3):326\u201331.","journal-title":"J Nucl Med"},{"issue":"4","key":"1390_CR56","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/annonc\/mdv577","volume":"27","author":"G Gebhart","year":"2016","unstructured":"Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27(4):619\u201324.","journal-title":"Ann Oncol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01390-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:04:36Z","timestamp":1775725476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01390-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1390"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01390-3","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee from the University of Duisburg\u2013Essen, medical faculty approved the study (ethics protocol permits 19-8991-BO and 20-9485-BO).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Alina T. K\u00fcper was supported by the Clinician Scientist Program of the University Medicine Essen Clinician Scientist Academy (UMEA; Faculty of Medicine and DFG), FU 356\/12\u2009\u2212\u20092. Anja Welt has received travel support from Pfizer and Lilly; is a member of the steering committee in the Breast cancer and Gynaecological cancer Track of the AIO (Arbeitsgemeinschaft Internistische Onkologie), of the DKG (Deutsche Krebsgesellschaft), and member of the Consensus Conference Update S3-Guideline Breast Cancer of the DKG; participated in advisory boards for MSD, Roche, Novartis, Pfizer, Seagen, Lilly, Menarini Stemline, Pierre Fabre; participated on a data safety monitoring board for iOMEDICO; received honoraria for lectures\/presentations from Roche, Eisai, Novartis, Pfizer, Lilly, Iomedico, Interplan, MSD, MCI, RCC, all outside of the submitted work. Ilectra A. Mavroeidi was supported by the Clinician Scientist Program of the University Medicine Essen Clinician Scientist Academy (UMEA; Faculty of Medicine and DFG), FU 356\/12\u2009\u2212\u20092. Rainer Hamacher was supported by the Clinician Scientist Program of the University Medicine Essen Clinician Scientist Academy (UMEA; Faculty of Medicine and DFG), FU 356\/12\u2009\u2212\u20092.; reports travel grants from Lilly, Novartis, and PharmaMar; and reports personal fees from Lilly and PharmaMar, all outside the submitted work. Kim M. Pabst was supported by the Clinician Scientist Program of the University Medicine Essen Clinician Scientist Academy (UMEA; Faculty of Medicine and DFG), FU 356\/12\u2009\u2212\u20092; reports travel fees from IPSEN; and reports research funding from Bayer, as well as travel support and consultant fees from Novartis, all outside the submitted work. Robert Seifert has received research\/travel support from Boehringer Ingelheim Fund and Else Kr\u00f6ner-Fresenius-Stiftung, as well as travel support and lecture fees from Novartis and Boston Scientific, all outside the submitted work. Lale Umutlu is a Speaker\/Advisory Board Member for Bayer Healthcare and Siemens Healthcare and received research grants from Siemens Healthcare, all outside of the submitted work. Martin Schuler reports personal fees as a consultant from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Roche, Sanofi, and Takeda; honoraria for continuing medical education presentations from Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, MSD, and Novartis; and research funding (to the institution) from AstraZeneca and Bristol Myers Squibb, all outside the submitted work. Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, all outside the submitted work. Wolfgang P. Fendler reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speaker), Perceptive (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant), Telix (speaker), GE Healthcare (speaker, consultant), Eczac\u0131ba\u015f\u0131 Monrol (speaker), Abx (speaker), Amgen (speaker, research funding), Urotrials (speaker), Lilly (consultant), AstraZeneca (research funding), all outside of the submitted work. Sherko K\u00fcmmel reports a consultant or advisory role with Roche\/Genentech, Genomic Health, Novartis, AstraZeneca, Amgen, Celgene, SOMATEX, Daiichi Sankyo, pfm medical, Pfizer, MSD Oncology, Lilly, Sonoscape, Gilead Sciences, Seagen, and Agendia. He also reports travel support and expenses from Roche, Daiichi Sankyo, and Gilead Sciences and an uncompensated relationship with WSG, all outside the submitted work. David Kersting reports fees from GE Healthcare (consultant, travel grants), Life Molecular Imaging and Sanofi (travel grants), Novartis (speaker), Pfizer (speaker, research funding), and funding by the German Research Foundation (DFG, KE2933\/1\u20131), all outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}